Skip to main content
BlogIn the News
 / 
In the News

Four Bold Predictions for Medtech in 2025: AI Everywhere, Faster Releases, and Rising Risks

Erez Kaminski
 and 
MPO News
  •  
December 18, 2024

Table of Contents

Four Bold Predictions for Medtech in 2025: AI Everywhere, Faster Releases, and Rising Risks

This article originally appeared in MPO News on December 18, 2024.

The Medtech industry stands at a crossroads. As artificial intelligence (AI) transforms all aspects of the tech world, Medtech executives are grappling with a high-stakes dilemma: adapt quickly or become irrelevant. But this transformation isn’t without risks – these trends may spell as much trouble for Medtechs as they do promise. While I won’t pretend to predict the future with certainty, here are four bold thoughts on the evolution of safety-critical software.

1. AI Becomes Standard, Not Just a Novelty

By the end of 2025, all major Medtech companies will have AI-enabled products. What was once a cutting-edge novelty is becoming table stakes, driven by intensifying competition and the pressure to innovate. AI will no longer be reserved for startups, experimental products, or niche applications; it will be embedded into devices across diagnostics, treatment planning, and patient monitoring.

But the rush to integrate AI comes with strings attached. Manufacturers aren’t just racing to develop these tools—they’re under immense pressure to ensure AI systems are safe, effective, secure, and compliant with increasingly complex regulations. Companies that fail to address these foundational challenges first will never be able to harness the power of AI in medicine.

Interview transcript

Erez Kaminski
Founder & CEO
Ketryx

Erez is passionate about improving patient care and health outcomes with software solutions. Over the last decade, Erez worked in industries including computational mathematics, biotech, and energy, helping build monitoring systems for pharmaceutical equipment and AI for medication management. Before Ketryx, Erez worked with Amgen, the world’s largest biotechnology company, as the head of AI/ML for their medical device division and with Wolfram Research, the builders of Mathematica and Wolfram|Alpha. Erez holds a Master of Science in Electrical Engineering and Computer Science and a Master of Business Administration from the Massachusetts Institute of Technology.